Ontology highlight
ABSTRACT:
SUBMITTER: Ababneh O
PROVIDER: S-EPMC9358782 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature
Ababneh Obada O Abushukair Hassan H Qarqash Aref A Syaj Sebawe S Al Hadidi Samer S
Clinical hematology international 20220523 1-2
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström's Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clinical outcomes and/or safety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhib ...[more]